Dr. Paul Limburg, a gastroenterology consultant at the Mayo Clinic, and CMO for screening at Exact Sciences, and co-author of this study discusses the results of the colorectal cancer screening study published in the Journal of Medical Screening. The study indicated high adherence to getting screened with the at-home, stool-based, multi-target DNA test. These findings point to the importance of choice in colorectal cancer (CRC) screening options, as well as the role of patient navigation programs to help with adherence, at a time when 1-in-3 individuals are not up to date on CRC screening.
Paul J. Limburg, M.D., is a consultant in the Division of Gastroenterology and Hepatology, with a joint appointment in the Division of Preventive, Occupational and Aerospace Medicine. He is a professor of medicine in the College of Medicine, Mayo Clinic. He is also the medical director of Mayo Clinic Global Business Solutions, medical director of the Preventive Services Clinic and principal investigator of the Cancer Prevention Network.Dr. Limburg’s clinical and research interests are focused on chronic disease prevention, with specific emphasis on chemoprevention, molecular epidemiology, and early detection.